Jerry Caulder

Jerry Caulder

Dr. Caulder started his professional career with Monsanto Company in 1969 where he held various positions until 1984. Between 1984-1998, he served as the President and Chief Executive Officer of Mycogen Corporation until it was sold to Dow Chemical Company. In 1998, Dr. Caulder became Executive Chairman and Chief Executive Officer of Myelos Neuroscience. He served Myelos until it was sold to Biotechnology General Corp. He has served as a member of several Boards of Directors and advisory boards, including Chairman of Cholorgen, Inc. and Athenix Corp., and advisor to New Zealand’s AgResearch and the Burrill Venture Capital Group.

Dr. Caulder is chairman of Kaypon, a venture capital company and finistere ventures, also a venture capital company. He also serves as chairman of SG Biofuels co, Algentix co., PhytoGro, co and ZeaKal, co., all plant science and bioenergy companies. Prior to that he served as chairman of the Industrial Biotechnology Association, a predecessor to the Biotechnology Industry Organization (BIO) and has served on BIO’s Board of Directors and chaired its Food and Agriculture Section. He has served on and chaired several committees of the U.S. Office of Technology Assessment and advised foreign governments on agriculture and biotechnology. He has been a consultant and speaker to numerous organizations, including the Brookings Institute, The Keystone Group and the World Economic Forum. He has been profiled in Forbes and USA Today and is frequently quoted in the national media.

Dr. Caulder earned his B.S. degree in Biology from Southeast Missouri State University and an M.S. and Ph.D. in Plant Physiology and Agronomy from the University of Missouri at Columbia.